BOTHELL, Wash., Sept. 28 /PRNewswire-FirstCall/ -- Cardiac Science (Nasdaq: CSCX), a global leader in advanced cardiac monitoring and defibrillation products, has been named to Deloitte's prestigious Technology Fast 50 Program for Washington State, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the region by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth from 2002-2006.
"Our revenue growth has been driven primarily by our defibrillation business and our cardiology connectivity solutions, complemented by acquisitions," said John Hinson, president and chief executive officer. "Through this strategy we have assembled a compelling portfolio of advanced diagnostic and therapeutic cardiology devices. We are proud of these achievements and are pleased to be recognized by Deloitte."
"Deloitte's Washington State Technology Fast 50 companies have shown the strength, vision and tenacity to succeed in today's very competitive technology environment," said Larry Hile, a partner with Deloitte & Touche LLP in Seattle. "We applaud the successes of Cardiac Science and acknowledge it as one of the very few to accomplish such a fast growth rate over the past five years."
Cardiac Science's increase in revenues of 234% from 2002 to 2006 resulted in a #17 ranking in the Technology Fast 50 for Washington State.
To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2002 and $5,000,000 in 2006, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.
Companies from the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit http://www.fast500.com.
This year's Washington State Technology Fast 50 program is co-presented by Deloitte & Touche USA LLP and Perkins Coie, Citibank, AH&T Insurance and the Puget Sound Business Journal.
About Cardiac Science Corporation
Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor -- defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China and Manchester, United Kingdom.
Frost & Sullivan, the global growth consulting company, has awarded Cardiac Science its 2007 award for Global Excellence in ECG Monitoring, recognizing Cardiac Science's superior leadership and vision to provide superior healthcare solutions in the cardiac monitoring market.
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte", "Deloitte & Touche", "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.
Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.
Forward Looking Statements
This press release contains forward-looking statements. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that Cardiac Science Corporation will continue to be successful in the marketplace, resulting in increasing revenues and profits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the 10-k filed by Cardiac Science Corporation for the year ended December 31, 2006.
The statements in this press release speak as of the date of the release, and Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
Cardiac Science Corporation
Sr. Vice President and CFO
EVC Group, Inc.
Douglas Sherk/Jenifer Kirtland
EVC Group, Inc.
|SOURCE Cardiac Science Corporation|
Copyright©2007 PR Newswire.
All rights reserved